drugset / Trial / NCT05566223
CISH Inactivated TILs in the Treatment of NSCLC
Non-randomizedSequentialOpen-labelTreatment
Summary
A clinical trial to assess the safety and efficacy of genetically-engineered Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Metastatic Non-small Cell Lung Cancer (NSCLC).
Timeline
- Start
- 2023-02
- Primary completion
- 2025-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CISH Inactivated TIL | Cell therapy | — | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Fludarabine | Small molecule | 25 mg/m2 | Intravenous |
| Background | aldesleukin | Protein / enzyme biologic | 720000 iu/kg | Intravenous |